CAPRICOR THERAPEUTICS, INC. (CAPR) FY2025 10-K Annual Report
CAPRICOR THERAPEUTICS, INC. (CAPR) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 17, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
CAPRICOR THERAPEUTICS, INC. FY2025 10-K Analysis
Business Overview
- • Core business model: development and manufacturing of cell-based therapies and exosome technologies, focus on Deramiocel for commercial and clinical use
- • New emphasis on potential vaccine candidates using exosome technologies with unique manufacturing and regulatory challenges highlighted
Management Discussion & Analysis
- • No specific revenue figures or YoY changes disclosed in provided text
- • No profitability, margin, or segment performance metrics mentioned
Risk Factors
- • Regulatory risk: FDA Complete Response Letter in July 2025 for Deramiocel BLA, requiring additional Phase 3 HOPE-3 trial data, new PDUFA date August 22, 2026
- • Geopolitical/macro risk: Exposure to U.S. public health policy through NIH/NIAID collaboration on StealthX™ vaccine under Project NextGen initiative
CAPRICOR THERAPEUTICS, INC. FY2025 Key Financial MetricsXBRL
Revenue
$0
▼ -100.0% YoY
Net Income
-$105M
▼ -159.6% YoY
ROE
-34.4%
▼ -653bp YoY
Total Assets
$356M
▲ +108.8% YoY
EPS (Diluted)
$-2.26
▼ -96.5% YoY
Operating Cash Flow
-$70M
▼ -74.5% YoY
Source: XBRL data from CAPRICOR THERAPEUTICS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on CAPRICOR THERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.